The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iablonskaia A.Iu.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Fedorova N.V.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo, Moskva

Bel'gusheva M.É.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease

Authors:

Iablonskaia A.Iu., Fedorova N.V., Bel'gusheva M.É.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7): 24‑30

Read: 2312 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFECT OF AMANTADINE SULFATE ON COGNITIVE DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE
THE EFFECT OF AMANTADINE SULFATE ON COGNITIVE DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE

To cite this article:

Iablonskaia AIu, Fedorova NV, Bel'gusheva MÉ. The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7):24‑30. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

Cognitive disorders in Parkinson's disease (PD) lead to occupational, social, everyday and psychological maladaptation in patients and their relatives. The paper addresses the epidemiology, structure and character of cognitive disorders in PD. The main pathogenetic factors of the development of moderate cognitive disorders and dementia in PD, methods of diagnosis and assessment of cognitive disorders and approaches to treatment of memory and intellect impairment are considered. We present the results of our own study on the effect of amantadine sulfate, prescribed in the dosage of 300 mg during 6 months, on cognitive disorders in 25 PD patients. Results of the therapy were assessed using neuropsychological tests and scales (MMSE, the Frontal Assessment battery, the Mattis dementia rating scale). The significant improvement in neuropsychological performance was seen in patients with moderate cognitive disorders treated with amantadine sulfate during 6 months.

Keywords:

Parkinson's disease
cognitive disorders
treatment
amantadine sulfate

Authors:

Iablonskaia A.Iu.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Fedorova N.V.

NII skoroĭ pomoshchi im. N.V. Sklifosovskogo, Moskva

Bel'gusheva M.É.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Close metadata

References:

  1. Arakelyan R.K., Nerobkova E.A., Katunina E.A. Funktsional'naya aktivnost' golovnogo mozga u patsienta s bolezn'yu Parkinsona pri lechenii sul'fatom amantadina. Zhurn nevrol i psikhiat 2005; 4.
  2. Artem'ev D.V., Glozman Zh.M. Narusheniya vysshikh psikhicheskikh funktsii pri bolezni Parkinsona. V sb.: Dostizheniya v neirogeriatrii. Pod red. N.N. Yakhno, I.V. Damulina. M 1995; 1: 46-58.
  3. Damulin I.V. Dementsiya pri bolezni Parkinsona. Metod. posobie dlya vrachei. M 2005.
  4. Zakharov V.V. Dementsiya pri bolezni Parkinsona. Nevrol zhurn (prilozhenie 1) 2006; 11:13-18.
  5. Zakharov V.V. Narushenie kognitivnykh funktsii pri bolezni Parkinsona i simptomaticheskom parkinsonizme: Dis. … d-ra med. nauk. M 2003; 36-40.
  6. Zakharov V.V., Yaroslavtseva P.V., Yakhno N.N. Kognitivnye narusheniya pri bolezni Parkinsona. Nevrol zhurn 2003; 2: 11-15.
  7. Zakharov V.V., Yakhno N.N. Sindrom umerennykh kognitivnykh rasstroistv v pozhilom vozraste: diagnostika i lechenie. Rus med zhurn 2004; 10: 573-576.
  8. Levin O.S., Batukaeva L.A., Smolentseva I.G. Diagnostika i lechenie dementsii pri bolezni Parkinsona. Zhurn nevrol i psikhiat 2008; 6: 91-97.
  9. Levin O.S., Golubeva L.V. Geterogennost' umerennogo kognitivnogo rasstroistva: diagnosticheskie i terapevticheskie aspekty. Konsilium 2006; 12: 106-110.
  10. MKB 10. Mezhdunarodnaya statisticheskaya klassifikatsiya boleznei i problem, svyazannykh so zdorov'em, 10-i peresmotr. Tom 1. Zheneva: VOZ 1995.
  11. Pilipovich A.A., Golubev V.L. Vliyanie pronorana na kognitivnye i affektivnye narusheniya pri bolezni Parkinsona. Zhurn nevrol i psikhiat 2005; 4: 41-47.
  12. Sadikova A.N. Korrektsiya klinicheskikh, neiropsikhologicheskikh, komp'yuterno-tomograficheskikh dannykh pri bolezni Parkinsona: Dis… kand. med. nauk. M 1997.
  13. Stepkina A.D., Zakharov V.V., Yakhno N.N. Kognitivnye narusheniya pri progressirovanii bolezni Parkinsona. Zhurn nevrol i psikhiat 2005;10: 13-19.
  14. Yakhno N.N. Kognitivnye rasstroistva v nevrologicheskoi klinike. Nevrol zhurn (prilozhenie 1) 2006; 11: 4-12.
  15. Benton A.L., Varney N.R., Hamsher K. Visuospatial judjement: a clinical test. Arch Neurol 1978; 35: 364-367.
  16. Bronnick K., Emre M., Lane R. et al. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiat 2007; 78: 1064-1068.
  17. Caspar P., Duyckaens et al. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinsons disease. Ann Neurol 1991; 30: 365-374.
  18. Cummings J.L. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiat 2005; 76: 903-904.
  19. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000; 55: 1621-1626.
  20. Emre M., Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson disease. Mov Dis 2007; 22: 1689-1707.
  21. Erme M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237.
  22. Fahn S., Eiton R. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disearse. S.Fahn, C. Marsden, D. Calne et al. (eds). McMillan Healthcare Information 1987; 5: 153-163.
  23. Folstein M.F., Folstein S.E., McHugh P.R. Mini-Mental State: a practical guide for grading the mental state of patients for the clinician. J Psychiat Res 1975; 12: 189-198.
  24. Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67: 1605-1611.
  25. Gianutsos G., Chute S., Dunne J.P. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 1985; 110: 357-361.
  26. Golomb J., Kluger A., Ferris S.H. Cllinican's Manual on Mild Cognitive Impairment. London: Science Press 2001.
  27. Hobson P., Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Dis 2004; 19: 1043-1049.
  28. Hoehn M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 5: 427-442.
  29. Inzelberg R., Bonuccelli U. et al. Association Between Amantadine and the Onset of dementia in Parkinsons disease. Mov Dis 2006; 2: 9: 1375-1379.
  30. Jacobs D.M., Marder K., Cote L. et al. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology 1995; 45: 1691-1696.
  31. Kaplan J., Goodglass H., Weintraub S. The Boston Naming test. Boston 1978.
  32. Le Bars P.L., Katz M.M., Berman N. A Placebo-controlled, double-blind, randomized trial of an extract of Gingo Biloba for dementia. JAMA 1997; 278: 1327-1332.
  33. Lewy G., Jacobs D.M. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Dis 2002; 17: 6: 1221-1226.
  34. Lezak M.D. Neuropsychology Assessment New York. NY: University Press 1983; 768.
  35. Malone M.A., Kerchner J., Swanson J.M. Hemispheric processing and methylphenidate effects in attention deficit hyperactivity disorder. J Child Neurol 1997; 9: 2: 181.
  36. Marder K., Tang M.X., Cote L., Stern Y. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52:695-701.
  37. Mattis S. Mental state examination for organic mental syndrome in the elderly patients. Ger Psychiaty. L. Bellack, T. B. Karasu (eds). New York 1976.
  38. Palmer K., Jelic V., Winblad B. Preface: mild cognitive impairment. Acta Neurol Scand 2003; 107 (Suppl 179): 5-6.
  39. Peppard R.F., Martin W.R., Carr G.D. et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992; 49: 1262-1268.
  40. Petersen R.S., Smith G.E., Waring S.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
  41. Petersen R.S., Touchon J. Consensus on mild cognitive impairment. Res Pract Alzheimer's Dis 2005; 10: 24-32.
  42. Poewe W., Wolters E., Emre M. et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Dis 2006; 21: 4: 456-461.
  43. von Voigtlander P. R., Moore K.E. Dopamine release from the brain in vivo by amantadine. Science 1937; 174: 408-410.
  44. Young A.B. et al. In excitatory amino acids and synaptic transmission. New York: Academic Press-Harccourt-Brace and Co. 29-40.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.